The immuno-oncology drug ‘Keytruda’ is finally on its next step to reimbursement after passing Cancer Disease Deliberation Committee's review.

According to industry sources, reimbursement expansion of MSD Korea’s PD-1 inhibitor Keytruda (pembrolizumab) will be deliberated by the National Health Insurance Service’s Drug Reimbursement Evaluation Committee on the 13th of this month.

Keytruda was able to finally reach the DREC doorsteps, six months after the agenda passed the CDDC meeting last July and four years after it first applied for the reimbursement expansion to its indications including as first-line treatment in non-small cell cancer (NSCLC)

Since MSD failed to